The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.40
Ask: 66.00
Change: -1.50 (-2.27%)
Spread: 2.60 (4.101%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Yourgene Health plc

8 Sep 2023 12:00

RNS Number : 8668L
Stifel Nicolaus Europe Limited
08 September 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Stifel Nicolaus Europe Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Yourgene Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Yourgene Health plc

(d) Date dealing undertaken:

07 September 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary

Buy

587,379

0.5126 GBX

0.5126 GBX

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

Date of disclosure:

08 September 2023

Contact name:

Jordan Gaskell

Telephone number:

0207 710 7482

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEREAPNPEFLDEEA
Date   Source Headline
14th Jun 20192:45 pmRNSConversion of Loan Notes
3rd Jun 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
24th May 20197:00 amRNSPublication of Annual Report and Notice of AGM
17th May 20194:35 pmRNSConversion of Loan Notes
15th May 20195:30 pmRNSConversion of Loan Notes
13th May 20197:00 amRNSLaunch of Next-Generation qPCR Instrument
3rd May 20196:23 pmRNSConversion of Loan Notes
3rd May 20197:00 amRNSChange of Adviser
1st May 20195:30 pmRNSLiquidity Agreement
30th Apr 20197:00 amRNSFull Year 2018 Results
25th Apr 20197:00 amRNSUpdate on Notice of Full Year Results
23rd Apr 20197:00 amRNSConvertible Bond Facility
8th Apr 20197:00 amRNSExpanded Development Partnership with Immunexpress
1st Apr 20192:30 pmRNSLiquidity Agreement and Total Voting Rights
4th Mar 20197:00 amRNSLiquidity Agreement and Total Voting Rights
26th Feb 20197:00 amRNSFunding Update
1st Feb 20192:00 pmRNSLiquidity Agreement and Total Voting Rights
22nd Jan 20197:00 amRNSRevenues Full Year 2018
2nd Jan 201912:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Dec 20187:00 amRNSTrading Update
21st Dec 20187:00 amRNSNovacyt launches two new molecular diagnostic kits
11th Dec 20187:00 amRNSUpdate on Strategic Review
6th Dec 20187:00 amRNSCompletion of q16 molecular diagnostics order
3rd Dec 20181:00 pmRNSLiquidity Agreement and Total Voting Rights
30th Nov 201812:06 pmRNSReplacement: Unsecured Debt Facility
27th Nov 20187:00 amRNS$3.0M supply agreement with Genesis Diagnostics
1st Nov 20185:45 pmRNSLiquidity Agreement
1st Oct 201810:51 amRNSLiquidity Agreement and Total Voting Rights
26th Sep 20187:00 amRNSNovacyt Half Year 2018 Results
13th Sep 20187:00 amRNSNovacyt Partners with Applied Microarrays
3rd Sep 201811:15 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 201810:30 amRNSLiquidity Agreement and Total Voting Rights
2nd Aug 20187:00 amRNSHalf Year Revenue Update
26th Jul 20187:00 amRNSRevenue update to be announced on 2 August 2018
2nd Jul 201811:45 amRNSLiquidity Agreement Update and Total Voting Rights
28th Jun 20187:00 amRNSAcquisition of ID Business from Omega Diagnostics
12th Jun 201811:45 amRNSReplacement - Results of Annual General Meeting
12th Jun 20187:00 amRNSResults of Annual General Meeting
5th Jun 20187:00 amRNSLaunch of New Product in Infectious Mononucleosis
1st Jun 20183:30 pmRNSLiquidity Agreement and Total Voting Rights
30th May 20186:30 pmRNSNew Unsecured Debt Facility
23rd May 20182:51 pmRNSPublication of Annual Report and Notice of AGM
1st May 20184:30 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Apr 20187:00 amRNSNovacyt Full Year 2017 Results
3rd Apr 20181:30 pmRNSLiquidity Agreement Update and Total Voting Rights
22nd Mar 20187:00 amRNSSigning of Assay Development Contract with GenePOC
1st Mar 20182:59 pmRNSLiquidity Agreement Update and Total Voting Rights
1st Feb 20183:15 pmRNSLiquidity Agreement Update and Total Voting Rights
26th Jan 20189:32 amRNSNotification of major holdings
24th Jan 20187:00 amRNSNOVACYT REVENUES FULL YEAR 2017

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.